KR102610491B1 - 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체 - Google Patents

뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체 Download PDF

Info

Publication number
KR102610491B1
KR102610491B1 KR1020177031660A KR20177031660A KR102610491B1 KR 102610491 B1 KR102610491 B1 KR 102610491B1 KR 1020177031660 A KR1020177031660 A KR 1020177031660A KR 20177031660 A KR20177031660 A KR 20177031660A KR 102610491 B1 KR102610491 B1 KR 102610491B1
Authority
KR
South Korea
Prior art keywords
compound
mmol
chloro
formula
methoxyphenyl
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020177031660A
Other languages
English (en)
Korean (ko)
Other versions
KR20180002644A (ko
Inventor
바르트 루돌프 로마니에 케스텔레인
쟝-프랑수아 봉팡티
팀 휴고 마리아 욘커스
피에르 쟝-마리 베르나르 라보이송
도로테 엘리스 마리에-에바 바르디오트
아르노 디디에 엠 마르샹
Original Assignee
얀센 파마슈티칼즈, 인코포레이티드
카톨리에케 유니버시테이트 루벤
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 얀센 파마슈티칼즈, 인코포레이티드, 카톨리에케 유니버시테이트 루벤 filed Critical 얀센 파마슈티칼즈, 인코포레이티드
Priority to KR1020217011966A priority Critical patent/KR102610493B1/ko
Publication of KR20180002644A publication Critical patent/KR20180002644A/ko
Application granted granted Critical
Publication of KR102610491B1 publication Critical patent/KR102610491B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/14—Radicals substituted by nitrogen atoms, not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
    • A61K31/404—Indoles, e.g. pindolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04—Indoles; Hydrogenated indoles
    • C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
    • C07D209/12—Radicals substituted by oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/08—Bridged systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/08—Bridged systems
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Virology (AREA)
  • Epidemiology (AREA)
  • Communicable Diseases (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Molecular Biology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1020177031660A 2015-05-08 2016-05-04 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체 Active KR102610491B1 (ko)

Priority Applications (1)

Application Number Priority Date Filing Date Title
KR1020217011966A KR102610493B1 (ko) 2015-05-08 2016-05-04 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
EP15166900 2015-05-08
EP15166900.9 2015-05-08
EP16163342.5 2016-03-31
EP16163342 2016-03-31
PCT/EP2016/059975 WO2016180696A1 (en) 2015-05-08 2016-05-04 Mono- or di-substituted indole derivatives as dengue viral replication inhibitors

Related Child Applications (1)

Application Number Title Priority Date Filing Date
KR1020217011966A Division KR102610493B1 (ko) 2015-05-08 2016-05-04 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체

Publications (2)

Publication Number Publication Date
KR20180002644A KR20180002644A (ko) 2018-01-08
KR102610491B1 true KR102610491B1 (ko) 2023-12-06

Family

ID=56026812

Family Applications (2)

Application Number Title Priority Date Filing Date
KR1020177031660A Active KR102610491B1 (ko) 2015-05-08 2016-05-04 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체
KR1020217011966A Active KR102610493B1 (ko) 2015-05-08 2016-05-04 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체

Family Applications After (1)

Application Number Title Priority Date Filing Date
KR1020217011966A Active KR102610493B1 (ko) 2015-05-08 2016-05-04 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체

Country Status (39)

Country Link
US (5) US10696632B2 (enExample)
EP (2) EP3294738B1 (enExample)
JP (4) JP6752821B2 (enExample)
KR (2) KR102610491B1 (enExample)
CN (3) CN107873022B (enExample)
AU (2) AU2016259677B2 (enExample)
BR (1) BR112017023904A2 (enExample)
CA (1) CA2981845C (enExample)
CL (1) CL2017002817A1 (enExample)
CO (1) CO2017012381A2 (enExample)
CR (2) CR20170490A (enExample)
CY (1) CY1124548T1 (enExample)
DK (1) DK3294738T3 (enExample)
EA (1) EA034978B1 (enExample)
EC (2) ECSP17073878A (enExample)
ES (2) ES2877404T3 (enExample)
GT (1) GT201700234A (enExample)
HR (1) HRP20210675T1 (enExample)
HU (1) HUE054724T2 (enExample)
IL (2) IL255430B (enExample)
JO (2) JOP20160086B1 (enExample)
LT (1) LT3294738T (enExample)
MD (1) MD3294738T2 (enExample)
MX (2) MX383932B (enExample)
MY (1) MY198339A (enExample)
NI (1) NI201700137A (enExample)
PE (2) PE20180232A1 (enExample)
PH (1) PH12017502000A1 (enExample)
PL (1) PL3294738T3 (enExample)
RS (1) RS62029B1 (enExample)
SG (1) SG10201900315SA (enExample)
SI (1) SI3294738T1 (enExample)
SM (1) SMT202100367T1 (enExample)
SV (1) SV2017005557A (enExample)
TW (2) TWI725969B (enExample)
UA (2) UA121332C2 (enExample)
UY (2) UY36674A (enExample)
WO (1) WO2016180696A1 (enExample)
ZA (2) ZA201707524B (enExample)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201116559D0 (en) 2011-09-26 2011-11-09 Univ Leuven Kath Novel viral replication inhibitors
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
PT3201176T (pt) * 2014-10-01 2019-03-04 Janssen Pharmaceuticals Inc Derivados indol mono- ou dissubstituídos como inibidores da replicação viral do dengue
DK3201177T3 (en) * 2014-10-01 2019-03-04 Janssen Pharmaceuticals Inc MONO OR DISUBSTITUTED INDOLES AS INHIBITORS OF DENGUE VIRUS REPLICATION
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SG11201808138YA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole derivatives as dengue viral replication inhibitors
MA44498A (fr) 2016-03-31 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3436004B1 (en) 2016-04-01 2024-12-11 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SI3630724T1 (sl) 2017-05-22 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors
CN114980884A (zh) 2019-11-15 2022-08-30 杨森制药公司 登革热疾病的治疗和预防
WO2022094816A1 (en) 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Solid formulation
WO2022094817A1 (en) * 2020-11-04 2022-05-12 Janssen Pharmaceuticals, Inc. Pharmaceutical formulation
CN113024440B (zh) * 2021-03-17 2023-05-16 凯莱英医药集团（天津）股份有限公司 连续化合成取代吲哚-2-羧酸的方法
AU2022304189A1 (en) 2021-06-29 2024-02-15 Janssen Pharmaceuticals, Inc. Processes for the preparation of (s)-2-(4-chloro-2-methoxyphenyl)-2-((3-methoxy-5-(methylsulfonyl)phenyl)amino)-1 -(1h-indol-3-yl)ethenone derivatives
AU2023269343A1 (en) 2022-05-12 2025-01-02 Janssen Pharmaceuticals, Inc. Treatment or prevention of dengue viral infection
CN115521307B (zh) * 2022-09-30 2023-09-22 甘肃皓天医药科技有限责任公司 一种5-卤代-7-氮杂吲哚的制备方法
WO2025253267A1 (en) 2024-06-06 2025-12-11 Janssen Pharmaceuticals, Inc. Combination of mosnodenvir and close analogs with nitd-688 for use in the treatment and prevention of dengue disease
WO2026018176A1 (en) 2024-07-17 2026-01-22 Janssen Pharmaceuticals, Inc. 2-(4-chloro-2 methoxyphenyl)-2-((3-methoxy-5-(methylsulfonyl)phenyl)amino)-1-(5-(trifluoro¬methoxy)-1h-indol-3-yl)ethanone and pharmaceutical compositions comprising the same
WO2026057013A1 (zh) * 2024-09-14 2026-03-19 华武生物医药技术(湖北)有限责任公司 一类登革热病毒复制抑制剂、其制备方法和用途
CN119306651B (zh) * 2024-10-11 2025-12-05 山东大学 一种吲哚3-酰胺类衍生物及其制备方法与应用
CN121378100B (zh) * 2025-12-24 2026-04-21 浙江大学医学院附属第二医院 一种苯并[g]吲哚衍生物及其在制备抗登革热药物中的应用

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013045516A1 (en) 2011-09-26 2013-04-04 Katholieke Universiteit Leuven Viral replication inhibitors

Family Cites Families (48)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2001520998A (ja) 1997-10-27 2001-11-06 イーライ・リリー・アンド・カンパニー インドールｓＰＬＡ２阻害剤のモルホリノ−Ｎ−エチルエステルプロドラッグ
GB0110832D0 (en) 2001-05-03 2001-06-27 Virogen Ltd Antiviral compounds
JP2005520795A (ja) 2001-12-12 2005-07-14 コンフォーマ・セラピューティクス・コーポレイション Ｈｓｐ９０阻害活性を有するプリン類似体
GB0215293D0 (en) 2002-07-03 2002-08-14 Rega Foundation Viral inhibitors
US20060211698A1 (en) 2005-01-14 2006-09-21 Genelabs, Inc. Bicyclic heteroaryl derivatives for treating viruses
AU2006221080A1 (en) 2005-02-09 2006-09-14 Migenix Inc. Compositions and methods for treating or preventing flaviviridae infections
FR2928645A1 (fr) * 2008-03-14 2009-09-18 Sanofi Aventis Sa Nouveaux derives de carbazole inhibiteurs d'hsp90, compositions les contenant et utilisation
AU2009256390A1 (en) 2008-06-03 2009-12-10 Siga Technologies, Inc. Small molecule inhibitors for the treatment or prevention of dengue virus infection
PE20110368A1 (es) * 2008-08-18 2011-06-13 Univ Yale Moduladores de mif
US8143259B2 (en) 2008-08-19 2012-03-27 Janssen Pharmaceutica, Nv Cold menthol receptor antagonists
TWI453207B (zh) 2008-09-08 2014-09-21 Signal Pharm Llc 胺基三唑并吡啶，其組合物及使用其之治療方法
WO2010091413A1 (en) 2009-02-09 2010-08-12 Enanta Pharmaceuticals, Inc. Linked dibenzimidazole derivatives
GB0910003D0 (en) 2009-06-11 2009-07-22 Univ Leuven Kath Novel compounds for the treatment of neurodegenerative diseases
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
KR20120123678A (ko) 2010-01-15 2012-11-09 길리애드 사이언시즈, 인코포레이티드 플라비비리다에 바이러스의 억제제
US20130023532A1 (en) 2010-03-26 2013-01-24 Casillas Linda N Indazolyl-pyrimidines as kinase inhibitors
JP5716205B2 (ja) 2011-03-29 2015-05-13 学校法人日本大学 グルコシダーゼ活性阻害用組成物及びそのスクリーニング方法
GB201305376D0 (en) 2013-03-25 2013-05-08 Univ Leuven Kath Novel viral replication inhibitors
MX368158B (es) 2013-10-23 2019-09-20 Janssen Sciences Ireland Uc Derivados de carboxamida y su uso como medicamentos para el tratamiento de la hepatitis b.
KR20240017118A (ko) 2014-01-31 2024-02-06 브리스톨-마이어스 스큅 컴퍼니 인자 XIa 억제제로서의 헤테로시클릭 P2' 기를 갖는 마크로사이클
SG10202113019XA (en) 2014-06-04 2021-12-30 Amgen Inc Methods for harvesting mammalian cell cultures
JP6641299B2 (ja) 2014-06-04 2020-02-05 フレッド ハッチンソン キャンサー リサーチ センター Ｎｏｔｃｈ １および／またはＮｏｔｃｈ ２アゴニストを用いた幹細胞の増殖および生着
PT3201176T (pt) 2014-10-01 2019-03-04 Janssen Pharmaceuticals Inc Derivados indol mono- ou dissubstituídos como inibidores da replicação viral do dengue
DK3201177T3 (en) 2014-10-01 2019-03-04 Janssen Pharmaceuticals Inc MONO OR DISUBSTITUTED INDOLES AS INHIBITORS OF DENGUE VIRUS REPLICATION
NO2721243T3 (enExample) 2014-10-01 2018-10-20
EP3204517B1 (en) 2014-10-10 2021-08-11 Rutgers, the State University of New Jersey Polymerase chain reaction primers and probes for mycobacterium tuberculosis
PH12017501272B1 (en) * 2015-01-16 2023-01-11 Janssen Pharmaceuticals Inc Indole derivatives as dengue viral replication inhibitors
AR103680A1 (es) 2015-02-23 2017-05-24 Lilly Co Eli Inhibidores selectivos de bace1
JOP20160086B1 (ar) * 2015-05-08 2021-08-17 2 Katholieke Univ Leuven Ku Leuven Research And Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
ES2952726T3 (es) 2015-07-22 2023-11-03 Omeicos Therapeutics Gmbh Análogos metabólicamente fuertes de CYP-eicosanoides para el tratamiento de enfermedad cardíaca
JO3633B1 (ar) 2015-09-16 2020-08-27 Katholieke Univ Leuven Ku Leuven Research & Development مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20160198B1 (ar) 2015-09-16 2022-03-14 Janssen Pharmaceuticals Inc مشتقات اندول مستبدلة احاديا او ثنائيا بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
EP3370698B1 (en) 2015-11-03 2022-01-26 Zoetis Services LLC Sol-gel polymer composites and uses thereof
SG11201808138YA (en) 2016-03-31 2018-10-30 Janssen Pharmaceuticals Inc Substituted indole derivatives as dengue viral replication inhibitors
MY194647A (en) 2016-03-31 2022-12-09 Takeda Pharmaceuticals Co Heterocyclic compound
MA44498A (fr) 2016-03-31 2019-02-06 Janssen Pharmaceuticals Inc Dérivés d'indoline substituée utilisés en tant qu'inhibiteurs de la réplication du virus de la dengue
JOP20170069B1 (ar) 2016-04-01 2021-08-17 1 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
CA3015934A1 (en) 2016-04-01 2017-10-05 Basf Se Bicyclic compounds
EP3436004B1 (en) 2016-04-01 2024-12-11 Janssen Pharmaceuticals, Inc. Substituted indole compound derivatives as dengue viral replication inhibitors
KR102608405B1 (ko) 2016-04-01 2023-12-01 카이트 파마 인코포레이티드 키메라 수용체 및 그의 사용 방법
BR112018070163A2 (pt) 2016-04-01 2019-01-29 Signal Pharm Llc compostos de aminopurina substituída, composições e métodos de tratamento
KR102694879B1 (ko) 2016-04-01 2024-08-16 암젠 인크 Flt3에 대한 키메라 수용체 및 이의 사용 방법
US10603380B2 (en) 2016-04-01 2020-03-31 Kite Pharma, Inc. Chimeric antigen and T cell receptors and methods of use
JP6573745B2 (ja) 2017-03-17 2019-09-11 三菱電機株式会社 アダプティブアレーアンテナ装置
JOP20180025B1 (ar) 2017-03-31 2021-08-17 Janssen Pharmaceuticals Inc مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
JOP20180026A1 (ar) 2017-03-31 2019-01-30 Univ Leuven Kath مشتقات اندولين مستبدلة بصفتها مانعات للتكاثر الفيروسي لحمى الفنك
SI3630724T1 (sl) 2017-05-22 2021-08-31 Janssen Pharmaceuticals, Inc. Substituirani derivati indolina kot zaviralci replikacije virusa denga
CA3060583C (en) 2017-05-22 2024-06-04 Janssen Pharmaceuticals, Inc. Substituted indoline derivatives as dengue viral replication inhibitors

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2013045516A1 (en) 2011-09-26 2013-04-04 Katholieke Universiteit Leuven Viral replication inhibitors

Also Published As

Publication number Publication date
EA034978B1 (ru) 2020-04-14
EP3896072A1 (en) 2021-10-20
US12172959B2 (en) 2024-12-24
KR102610493B1 (ko) 2023-12-05
JOP20210109A1 (ar) 2023-01-30
JP6752821B2 (ja) 2020-09-09
EP3294738A1 (en) 2018-03-21
AU2016259677B2 (en) 2020-10-01
CN113045476B (zh) 2024-07-16
RS62029B1 (sr) 2021-07-30
US10919854B2 (en) 2021-02-16
TW202041499A (zh) 2020-11-16
UA121332C2 (uk) 2020-05-12
ZA202002435B (en) 2023-03-29
PH12017502000B1 (en) 2018-03-26
KR20180002644A (ko) 2018-01-08
ECSP17073878A (es) 2018-02-28
CA2981845A1 (en) 2016-11-17
US20210171462A1 (en) 2021-06-10
ES2877404T3 (es) 2021-11-16
IL255430B (en) 2020-03-31
US11827602B2 (en) 2023-11-28
LT3294738T (lt) 2021-08-25
CA2981845C (en) 2022-03-08
GT201700234A (es) 2018-11-26
AU2020273314B2 (en) 2021-10-21
CN113045476A (zh) 2021-06-29
JP2020125316A (ja) 2020-08-20
US20250230127A1 (en) 2025-07-17
UA128183C2 (uk) 2024-05-01
UY39706A (es) 2022-05-31
TWI725969B (zh) 2021-05-01
JP7451626B2 (ja) 2024-03-18
EA201792429A1 (ru) 2018-02-28
MD3294738T2 (ro) 2021-08-31
IL272814A (en) 2020-04-30
MX383932B (es) 2025-03-14
CY1124548T1 (el) 2022-07-22
JOP20160086B1 (ar) 2021-08-17
ZA201707524B (en) 2024-06-26
SI3294738T1 (sl) 2021-08-31
SMT202100367T1 (it) 2021-07-12
DK3294738T3 (da) 2021-06-28
CN107873022B (zh) 2021-03-12
US20200270209A1 (en) 2020-08-27
PE20221579A1 (es) 2022-10-06
NZ765879A (en) 2024-09-27
CR20170490A (es) 2018-03-08
JP6898493B2 (ja) 2021-07-07
HK1252446A1 (zh) 2019-05-24
MY198339A (en) 2023-08-27
TWI744963B (zh) 2021-11-01
TW201704208A (zh) 2017-02-01
CR20200152A (es) 2020-09-08
AU2016259677A1 (en) 2017-10-26
HRP20210675T1 (hr) 2021-06-25
SV2017005557A (es) 2018-06-26
CN107873022A (zh) 2018-04-03
ECSP22023220A (es) 2022-05-31
EP3294738B1 (en) 2021-04-07
MX2020011156A (es) 2022-04-21
AU2020273314A1 (en) 2020-12-17
CL2017002817A1 (es) 2018-05-11
NZ736934A (en) 2023-11-24
CN111303000B (zh) 2023-11-28
HK1252496A1 (zh) 2019-05-31
PH12017502000A1 (en) 2018-03-26
MX391754B (es) 2025-03-21
CO2017012381A2 (es) 2018-03-28
MX2017014293A (es) 2018-08-09
US10696632B2 (en) 2020-06-30
EP3896072B1 (en) 2022-11-16
IL255430A0 (en) 2017-12-31
JP7132399B2 (ja) 2022-09-06
HUE054724T2 (hu) 2021-09-28
SG10201900315SA (en) 2019-02-27
CN111303000A (zh) 2020-06-19
NI201700137A (es) 2019-05-07
JP2021138752A (ja) 2021-09-16
KR20210048578A (ko) 2021-05-03
PL3294738T3 (pl) 2021-12-13
UY36674A (es) 2016-11-30
US20240182414A1 (en) 2024-06-06
WO2016180696A1 (en) 2016-11-17
IL272814B (en) 2021-02-28
JP2018515495A (ja) 2018-06-14
US20180346419A1 (en) 2018-12-06
BR112017023904A2 (pt) 2018-07-17
ES2941674T3 (es) 2023-05-24
JP2022166289A (ja) 2022-11-01
PE20180232A1 (es) 2018-01-31
JOP20210109B1 (ar) 2024-12-22

Similar Documents

Publication Publication Date Title
KR102610493B1 (ko) 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체
KR102478311B1 (ko) 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체
KR102676442B1 (ko) 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌 유도체
US10765662B2 (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
KR102478309B1 (ko) 뎅기 바이러스 복제 억제제로서의 １치환 또는 ２치환 인돌
KR102509848B1 (ko) 뎅기 바이러스 복제 억제제로서의 인돌 유도체
HK40052902B (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
HK40052902A (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
HK1252496B (en) Mono- or di-substituted indole derivatives as dengue viral replication inhibitors
EA040657B1 (ru) Производные моно- или дизамещенных индолов в качестве ингибиторов репликации вирусов денге

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20171031

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
AMND Amendment
A107 Divisional application of patent
PA0104 Divisional application for international application

Comment text: Divisional Application for International Patent

Patent event code: PA01041R01D

Patent event date: 20210422

A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20210423

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20230307

Patent event code: PE09021S01D

AMND Amendment
E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20230915

AMND Amendment
PX0701 Decision of registration after re-examination

Patent event date: 20231114

Comment text: Decision to Grant Registration

Patent event code: PX07013S01D

Patent event date: 20231010

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20230504

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20210423

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

Patent event date: 20190116

Comment text: Amendment to Specification, etc.

Patent event code: PX07012R01I

X701 Decision to grant (after re-examination)
GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20231201

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20231201

End annual number: 3

Start annual number: 1

PG1601 Publication of registration